The Indian government is set to introduce a production-linked incentive (PLI) scheme in 2026 aimed at promoting the domestic manufacturing of GLP-1 drugs. These drugs are primarily used in the treatment of diabetes and obesity. The initiative is part of a broader effort to boost local pharmaceutical manufacturing and reduce dependency on imports. A government official confirmed the plan, highlighting its potential impact on the healthcare sector in India. The PLI scheme specifically targets the production of drugs used for obesity and diabetes.
